Assays for and Reversal of New Anticoagulants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

New anticoagulants are being introduced to replace warfarin. These drugs do not require monitoring and are safer. There is currently no recommended way to reverse these drugs rapidly in the event of undue bleeding or need for emergency surgery. This is a lab study to look at ways to reverse the drugs rapidly

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist

NCT01348074

Atrial Fibrillation Venous Thromboembolism Heart Valve Disease +1 more

COMPLETED PHASE2

Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery

NCT00253851

DVT Osteoarthritis

COMPLETED PHASE4

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

NCT04878497

Atrial Fibrillation Frailty Anticoagulant-induced Bleeding +1 more

UNKNOWN

Reversal of the Antithrombotic Action of New Oral Anticoagulants

NCT01478282

Thrombosis Anticoagulant-induced Bleeding Anticoagulant Overdosage +1 more

UNKNOWN PHASE4

Study to Test the Accuracy of a Prototype Handheld PT/INR Device

NCT01349712

Blood Coagulation Disorders

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We are developing in vitro assays of measurement of the effect of these drugs on the relevant coagulation pathways in plasma; such assays are not widely established. This will then allow us to test potential reversing agents such as activated Factor VII (Novo-Seven®), or Factor VIII inhibitor bypassing agent (FEIBA) for their ability to reverse these anti-coagulants invitro. The aims of this reversal research strategy is to provide a means whereby patients who present with serious bleeding or who need rapid reversal for surgery, for example, can be offered such treatment to allow rapid normalisation of their coagulation system.

As part of this developmental programme, we wish to obtain samples from patients receiving Rivaroxaban or Dabigatran for therapeutic reasons, to test the effect of the respective drug on the relevant coagulation factors and to test in vitro reversibility.

The only requirement for the patient is to have an extra 20ml of blood taken at a time when the patient is having other blood tests. There are no risks or experimental procedures planned to be carried out on patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Osteoarthritis of the Knee Osteoarthritis of the Hip

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients receiving a new anticoagulant

Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Receiving dabigatran for atrial fibrillation
* Or,for osteoarthritis of the hip or knee receiving rivaroxaban to prevent thromboembolic disease after total hip or knee replacement respectively